W. Jeffrey Albers's Insider Trades & SAST Disclosures
W. Jeffrey Albers's most recent trade in Blueprint Medicines Corp was a trade of 7,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 12, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern W. Jeffrey Albers.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2025 | 7,500 | 97,500 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.05 per share. | 12 Mar 2025 | 7,500 | 159,896 (0%) | 0% | 36.1 | 270,375 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 87.62 per share. | 12 Mar 2025 | 5,700 | 154,196 (0%) | 0% | 87.6 | 499,434 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 88.37 per share. | 12 Mar 2025 | 1,800 | 152,396 (0%) | 0% | 88.4 | 159,066 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 88.80 per share. | 05 Mar 2025 | 5,766 | 146,630 (0%) | 0% | 88.8 | 512,021 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jan 2025 | 10,000 | 105,000 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.05 per share. | 21 Jan 2025 | 10,000 | 167,557 (0%) | 0% | 36.1 | 360,500 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 109.11 per share. | 21 Jan 2025 | 7,561 | 159,996 (0%) | 0% | 109.1 | 824,981 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 109.92 per share. | 21 Jan 2025 | 7,400 | 152,596 (0%) | 0% | 109.9 | 813,408 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 110.61 per share. | 21 Jan 2025 | 200 | 152,396 (0%) | 0% | 110.6 | 22,122 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.05 per share. | 13 Jan 2025 | 5,000 | 162,557 (0%) | 0% | 36.1 | 180,250 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 102.28 per share. | 13 Jan 2025 | 5,000 | 157,557 (0%) | 0% | 102.3 | 511,400 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2025 | 5,000 | 115,000 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Jeffrey Albers W. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2024 | 15,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.05 per share. | 19 Dec 2024 | 15,000 | 172,557 (0%) | 0% | 36.1 | 540,750 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 89.01 per share. | 19 Dec 2024 | 5,180 | 163,457 (0%) | 0% | 89.0 | 461,072 | Common Stock |
| Blueprint Medicines Corp | Albers Jeffrey W. | Director | Sale of securities on an exchange or to another person at price $ 88.28 per share. | 19 Dec 2024 | 3,920 | 168,637 (0%) | 0% | 88.3 | 346,058 | Common Stock |
| Blueprint Medicines Corp | W. Jeffrey Albers | Director | Sale of securities on an exchange or to another person at price $ 91.15 per share. | 19 Dec 2024 | 3,800 | 159,657 (0%) | 0% | 91.2 | 346,370 | Common Stock |
| Blueprint Medicines Corp | Jeffrey Albers W. | Director | Sale of securities on an exchange or to another person at price $ 91.96 per share. | 19 Dec 2024 | 2,100 | 157,557 (0%) | 0% | 92.0 | 193,116 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 102.00 per share. | 07 Nov 2024 | 5,000 | 157,557 (0%) | 0% | 102 | 510,000 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 5,000 | 135,000 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.05 per share. | 07 Nov 2024 | 5,000 | 162,557 (0%) | 0% | 36.1 | 180,250 | Common Stock |
| Spyre Therapeutics Inc. | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 36.76 per share. | 06 Nov 2024 | 6,700 | 27,360 (0%) | 0% | 36.8 | 246,313 | Common Stock |
| Spyre Therapeutics Inc. | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 36.43 per share. | 25 Oct 2024 | 300 | 34,060 (0%) | 0% | 36.4 | 10,929 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 85.86 per share. | 09 Sep 2024 | 11,968 | 165,291 (0%) | 0% | 85.9 | 1,027,572 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2024 | 10,000 | 140,000 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.05 per share. | 09 Sep 2024 | 10,000 | 177,259 (0%) | 0% | 36.1 | 360,500 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 85.12 per share. | 09 Sep 2024 | 7,734 | 157,557 (0%) | 0% | 85.1 | 658,318 | Common Stock |
| Kymera Therapeutics Inc | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2024 | 5,000 | 11,349 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 49.10 per share. | 26 Aug 2024 | 5,000 | 0 | - | 49.1 | 245,509 | Common Stock |
| Kymera Therapeutics Inc | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.34 per share. | 26 Aug 2024 | 5,000 | 5,000 | - | 10.3 | 51,700 | Common Stock |
| Kymera Therapeutics Inc | Jeffrey W. Albers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 16,000 | 16,000 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 4,570 | 4,570 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 2,242 | 167,259 (0%) | 0% | 0 | Common Stock | |
| Spyre Therapeutics Inc. | Jeffrey W. Albers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2024 | 11,323 | 11,323 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.87 per share. | 20 Mar 2024 | 15,073 | 191,123 (0%) | 0% | 1.9 | 28,187 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2024 | 15,073 | 0 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2024 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.01 per share. | 20 Mar 2024 | 10,000 | 201,123 (0%) | 0% | 15.0 | 150,100 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 87.26 per share. | 20 Mar 2024 | 8,440 | 183,702 (0%) | 0% | 87.3 | 736,474 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 88.60 per share. | 20 Mar 2024 | 6,285 | 177,417 (0%) | 0% | 88.6 | 556,851 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 86.46 per share. | 20 Mar 2024 | 6,251 | 192,142 (0%) | 0% | 86.5 | 540,461 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 85.22 per share. | 20 Mar 2024 | 2,730 | 198,393 (0%) | 0% | 85.2 | 232,651 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 89.12 per share. | 20 Mar 2024 | 1,367 | 176,050 (0%) | 0% | 89.1 | 121,827 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 90.69 per share. | 07 Mar 2024 | 11,033 | 165,017 (0%) | 0% | 90.7 | 1,000,583 | Common Stock |
| Kymera Therapeutics Inc | W. Albers Jeffrey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2024 | 4,385 | 16,349 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | W. Albers Jeffrey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.34 per share. | 20 Feb 2024 | 4,385 | 4,385 | - | 10.3 | 45,341 | Common Stock |
| Kymera Therapeutics Inc | W. Albers Jeffrey | Director | Sale of securities on an exchange or to another person at price $ 39.05 per share. | 20 Feb 2024 | 4,385 | 0 | - | 39.0 | 171,227 | Common Stock |
| Kymera Therapeutics Inc | Jeffrey Albers W. | Director | Sale of securities on an exchange or to another person at price $ 39.07 per share. | 20 Feb 2024 | 615 | 0 | - | 39.1 | 24,031 | Common Stock |
| Kymera Therapeutics Inc | Jeffrey Albers W. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.34 per share. | 20 Feb 2024 | 615 | 615 | - | 10.3 | 6,359 | Common Stock |
| Kymera Therapeutics Inc | W. Jeffrey Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2024 | 615 | 20,734 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Jeffrey Albers W. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2024 | 15,000 | 15,073 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | W. Jeffrey Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.87 per share. | 25 Jan 2024 | 15,000 | 191,050 (0%) | 0% | 1.9 | 28,050 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 81.70 per share. | 25 Jan 2024 | 10,890 | 184,074 (0%) | 0% | 81.7 | 889,713 | Common Stock |
| Blueprint Medicines Corp | Albers Jeffrey W. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2024 | 10,000 | 2,496 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Jeffrey Albers W. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.01 per share. | 25 Jan 2024 | 10,000 | 201,050 (0%) | 0% | 15.0 | 150,100 | Common Stock |
| Blueprint Medicines Corp | Albers Jeffrey W. | Director | Sale of securities on an exchange or to another person at price $ 82.76 per share. | 25 Jan 2024 | 7,924 | 176,150 (0%) | 0% | 82.8 | 655,790 | Common Stock |
| Blueprint Medicines Corp | Jeffrey Albers W. | Director | Sale of securities on an exchange or to another person at price $ 81.16 per share. | 25 Jan 2024 | 6,086 | 194,964 (0%) | 0% | 81.2 | 493,940 | Common Stock |
| Blueprint Medicines Corp | Albers W. Jeffrey | Director | Sale of securities on an exchange or to another person at price $ 83.57 per share. | 25 Jan 2024 | 100 | 176,050 (0%) | 0% | 83.6 | 8,357 | Common Stock |
| Kymera Therapeutics Inc | W. Albers Jeffrey | Director | Sale of securities on an exchange or to another person at price $ 30.05 per share. | 23 Jan 2024 | 10,000 | 0 | - | 30.0 | 300,470 | Common Stock |
| Kymera Therapeutics Inc | Albers W. Jeffrey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.34 per share. | 23 Jan 2024 | 10,000 | 10,000 | - | 10.3 | 103,400 | Common Stock |
| Kymera Therapeutics Inc | Albers Jeffrey W. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2024 | 10,000 | 21,349 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Albers Jeffrey W. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2023 | 5,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.05 per share. | 11 Dec 2023 | 5,000 | 181,050 (0%) | 0% | 36.1 | 180,250 | Common Stock |
| Blueprint Medicines Corp | W. Jeffrey Albers | Director | Sale of securities on an exchange or to another person at price $ 79.07 per share. | 11 Dec 2023 | 5,000 | 176,050 (0%) | 0% | 79.1 | 395,350 | Common Stock |
| Blueprint Medicines Corp | Albers W. Jeffrey | Director | Sale of securities on an exchange or to another person at price $ 70.55 per share. | 30 Nov 2023 | 5,000 | 176,050 (0%) | 0% | 70.6 | 352,750 | Common Stock |
| Blueprint Medicines Corp | Albers Jeffrey W. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2023 | 5,000 | 155,000 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.05 per share. | 30 Nov 2023 | 5,000 | 181,050 (0%) | 0% | 36.1 | 180,250 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Nov 2023 | 15,000 | 30,073 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.87 per share. | 24 Nov 2023 | 15,000 | 191,050 (0%) | 0% | 1.9 | 28,050 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 67.25 per share. | 24 Nov 2023 | 7,964 | 183,086 (0%) | 0% | 67.3 | 535,579 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 67.81 per share. | 24 Nov 2023 | 7,036 | 176,050 (0%) | 0% | 67.8 | 477,111 | Common Stock |
| Aeglea BioTherapeutics Inc | W. Jeffrey Albers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Nov 2023 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Aeglea BioTherapeutics Inc | W. Jeffrey Albers | Director | 22 Nov 2023 | 34,360 | 34,360 (0%) | 0% | 0 | Common Stock | ||
| Aeglea BioTherapeutics Inc | Albers Jeffrey W. | Director | 22 Nov 2023 | 859 | 0 | - | - | Series A Preferred Stock | ||
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2023 | 4,634 | 161,485 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.05 per share. | 01 Nov 2023 | 4,634 | 180,684 (0%) | 0% | 36.1 | 167,056 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 60.36 per share. | 01 Nov 2023 | 4,575 | 176,109 (0%) | 0% | 60.4 | 276,147 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2023 | 3,881 | 166,119 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 60.02 per share. | 01 Nov 2023 | 3,881 | 176,050 (0%) | 0% | 60.0 | 232,938 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.05 per share. | 01 Nov 2023 | 3,881 | 179,931 (0%) | 0% | 36.0 | 139,910 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.05 per share. | 01 Nov 2023 | 1,485 | 177,535 (0%) | 0% | 36.0 | 53,534 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2023 | 1,485 | 160,000 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 60.13 per share. | 01 Nov 2023 | 1,485 | 176,050 (0%) | 0% | 60.1 | 89,293 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 61.05 per share. | 01 Nov 2023 | 59 | 176,050 (0%) | 0% | 61.1 | 3,602 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Sep 2023 | 18,102 | 51,971 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.87 per share. | 27 Sep 2023 | 18,102 | 194,152 (0%) | 0% | 1.9 | 33,851 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 49.93 per share. | 27 Sep 2023 | 12,102 | 176,450 (0%) | 0% | 49.9 | 604,253 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 50.17 per share. | 27 Sep 2023 | 6,898 | 176,050 (0%) | 0% | 50.2 | 346,073 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.87 per share. | 27 Sep 2023 | 6,898 | 182,948 (0%) | 0% | 1.9 | 12,899 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Sep 2023 | 6,898 | 45,073 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 48.84 per share. | 27 Sep 2023 | 5,600 | 188,552 (0%) | 0% | 48.8 | 273,504 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 50.50 per share. | 27 Sep 2023 | 400 | 176,050 (0%) | 0% | 50.5 | 20,200 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Aug 2023 | 15,000 | 80,073 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.87 per share. | 24 Aug 2023 | 15,000 | 191,050 (0%) | 0% | 1.9 | 28,050 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 49.57 per share. | 24 Aug 2023 | 15,000 | 176,050 (0%) | 0% | 49.6 | 743,550 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.87 per share. | 24 Aug 2023 | 10,000 | 186,050 (0%) | 0% | 1.9 | 18,700 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Sale of securities on an exchange or to another person at price $ 50.16 per share. | 24 Aug 2023 | 10,000 | 176,050 (0%) | 0% | 50.2 | 501,600 | Common Stock |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Aug 2023 | 10,000 | 70,073 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 5,300 | 5,300 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Jeffrey W. Albers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 2,600 | 176,050 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges